EHA 2025
Jun 12 - 15, 2025 | Milan, Italy
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular LymphomaA Van Acker et al.